← FDA DRUG APPROVALS

FDA NDA · NDA020209

OXISTAT

oxiconazole nitrate

Sponsor: ANI PHARMS

APPLICATION
NDA020209
TYPE
NDA
ORIGINAL APPROVAL
1992-09-30
LATEST ACTION
2022-05-24
ROUTE
TOPICAL
DOSAGE FORM
LOTION
MARKETING STATUS
Discontinued

Products

OXISTAT · ReferenceDiscontinued
OXICONAZOLE NITRATE EQ 1% BASE · LOTION · TOPICAL

Approval history

2022-05-24Labeling · Supplement 14 · standardLetterAP
2015-08-19Manufacturing (CMC) · Supplement 10 · standardAP
2015-03-03Manufacturing (CMC) · Supplement 9 · standardAP
2015-01-26Manufacturing (CMC) · Supplement 8 · standardAP
2004-01-23Labeling · Supplement 5 · standardLetterAP
1997-08-08Manufacturing (CMC) · Supplement 4 · standardAP
1993-10-21Labeling · Supplement 1 · standardAP
1992-09-30Type 3 - New Dosage Form · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →